alexa
Reach Us +44-1904-929220
Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors | OMICS International | Abstract
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors

Yosuke Minami* and Tomoki Naoe

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

*Corresponding Author:
Yosuke Minami
Department of Hematology and Oncology
Nagoya University Graduate School of Medicine
65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
Tel: +81-52-744-2145
Fax: +81-52-744-2161
E-mail: [email protected]

Received date: April 22, 2012; Accepted date: May 05, 2012; Published date: May 12, 2012

Citation: Minami Y, Naoe T (2012) Biomarker Assay for Residual Chronic Myeloid Leukemia Stem/Progenitor Cells during Treatment with ABL-Tyrosine Kinase Inhibitors. J Mol Biomarkers Diagn S8:001.doi:10.4172/2155-9929.S8-001

Copyright: © 2012 Minami Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract

The use of tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM) targeted against BCR-ABL has proven
successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. However, several
mathematical models and ex-vivo examinations suggested that IM-therapy does not eradicate CML stem cells. We recently
reported the investigation of residual CML diseases during TKI treatment using FACS-sorting and quantitative RT-PCR of
BCR-ABL among each population; total mononuclear cells, hematopoietic stem cells, and myeloid progenitors. Moreover,
we need to develop the evaluation method of the residual CML stem cells to establish rational TKI-cessation strategies in
CML.

Keywords

Recommended Conferences

15th Global Biomarkers and Clinical Research Summit

Vienna, Austria

2nd International Conference on Biomarkers and Cancer Targets

Capetown, South Africa
Share This Page
Top